Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 5, Mai 2014
Page(s) 526 - 531
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143005015
Publié en ligne 13 juin 2014
  1. Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines in the US between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Am J Prev Med 2010 ; 39 : 228–234. [CrossRef] [PubMed]
  2. Wilson PW, Evans JC. Coronary artery disease prediction. Am J Hypertens 1993 ; 6 : 309S–313S. [CrossRef] [PubMed]
  3. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006 ; 86 : 515–581. [CrossRef] [PubMed]
  4. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011 ; 31 : 969–979. [CrossRef] [PubMed]
  5. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008 ; 77 : 495–520. [CrossRef] [PubMed]
  6. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009 ; 23 : 73–83. [CrossRef] [PubMed]
  7. McIntyre TM, Prescott SM, Stafforini DM. The emerging roles of PAF acetylhydrolase. J Lipid Res 2009 ; 50 Suppl : S255–S259. [CrossRef] [PubMed]
  8. Silva IT, Mello AP, Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)): a review. Lipids Health Dis 2011 ; 10 : 170. [CrossRef] [PubMed]
  9. Triggiani M, Granata F, Frattini A, Marone G. Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta 2006 ; 1761 : 1289–1300. [CrossRef] [PubMed]
  10. Kimura-Matsumoto M, Ishikawa Y, Komiyama K, et al. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis 2008 ; 196 : 81–91. [CrossRef] [PubMed]
  11. Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007 ; 27 : 600–606. [CrossRef] [PubMed]
  12. Webb NR, Bostrom MA, Szilvassy SJ, et al. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2003 ; 23 : 263–268. [CrossRef] [PubMed]
  13. Sato H, Kato R, Isogai Y, et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008 ; 283 : 33483–33497. [CrossRef] [PubMed]
  14. Ait-Oufella H, Herbin O, Lahoute C, et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2013 ; 33 : 466–473. [CrossRef] [PubMed]
  15. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010 ; 122 : 2183–2200. [CrossRef] [PubMed]
  16. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000 ; 343 : 1148–1155. [CrossRef] [PubMed]
  17. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 ; 375 : 1536–1544. [CrossRef] [PubMed]
  18. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005 ; 26 : 137–144. [CrossRef] [PubMed]
  19. Sabatine MS, Morrow DA, O’Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007 ; 27 : 2463–2469. [CrossRef] [PubMed]
  20. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007 ; 28 : 699–704. [CrossRef] [PubMed]
  21. O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006 ; 113 : 1745–1752. [CrossRef] [PubMed]
  22. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmo, Sweden. Atherosclerosis 2008 ; 200 : 191–198. [CrossRef] [PubMed]
  23. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2005 ; 165 : 2479–2484. [CrossRef] [PubMed]
  24. Wassertheil-Smoller S, Kooperberg C, McGinn AP, et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008 ; 51 : 1115–1122. [CrossRef] [PubMed]
  25. Elkind MS, Tai W, Coates K, et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006 ; 166 : 2073–2080. [CrossRef] [PubMed]
  26. Elkind MS, Tai W, Coates K, et al. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009 ; 27 : 42–50. [CrossRef] [PubMed]
  27. Cucchiara BL, Messe SR, Sansing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009 ; 40 : 2332–2336. [CrossRef] [PubMed]
  28. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007 ; 27 : 1177–1183. [CrossRef] [PubMed]
  29. Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2005 ; 25 : 839–846. [CrossRef] [PubMed]
  30. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999 ; 100 : 1280–1284. [CrossRef] [PubMed]
  31. Koenig W, Vossen CY, Mallat Z, et al. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009 ; 30 : 2742–2748. [CrossRef] [PubMed]
  32. MZ O’Donoghue ML, Morrow DA, Benessiano J, et al. The prognostic utility of secretory phospholipase A2 in patients with stable coronary artery disease. Circulation, 2009 ; 120 : S452.
  33. Kugiyama K, Ota Y, Sugiyama S, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000 ; 86 : 718–722. [CrossRef] [PubMed]
  34. Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005 ; 46 : 1249–1257. [CrossRef] [PubMed]
  35. Simon MZT, Kotti-Tounsi S, Benessiano J, et al. Impact of secretory PLA2-IIA gene polymorphisms on sPLA2 activity, cardiovascular events following an AMI: results from the French register of acute ST elevation or non-ST elevation myocardial infarction. Circulation 2009 ; 120 : S1174. [CrossRef]
  36. Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 2013 ; 62 : 1966–1976. [CrossRef] [PubMed]
  37. Varthaman A, Khallou-Laschet J, Thaunat O, et al. L’athérogenèse : une maladie dysimmunitaire. Med Sci (Paris) 2008 ; 24 : 169–176. [CrossRef] [EDP Sciences] [PubMed]
  38. Girard CA, Seitz-Polski B, Dolla G, et al. Nouveaux rôles physiopathologiques pour le récepteur PLA2R1 dans le cancer et la glomérulonéphrite extramembraneuse. Med Sci (Paris) 2014 ; 30 : 519–525. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.